Modeling and predicting drug pharmacokinetics in patients with renal impairment.
about
Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulationsApplication of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsDose selection based on physiologically based pharmacokinetic (PBPK) approaches.Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.Impact of special patient populations on the pharmacokinetics of echinocandins.Physiologically Based Pharmacokinetic (Pbpk) Model of the Cyp2d6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.Guidance to develop individual dose recommendations for patients on chronic hemodialysis.Cationic uremic toxins affect human renal proximal tubule cell functioning through interaction with the organic cation transporter.Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.Physiologically based and population PK modeling in optimizing drug development: A predict-learn-confirm analysis.Uremic Toxins Induce ET-1 Release by Human Proximal Tubule Cells, which Regulates Organic Cation Uptake Time-Dependently.Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development.In silico evaluation of gadofosveset pharmacokinetics in different population groups using the Simcyp® simulator platform.INDI: a computational framework for inferring drug interactions and their associated recommendations.Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.Physiologically based pharmacokinetic modelling to predict single- and multiple-dose human pharmacokinetics of bitopertin.Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence.Evaluation of Model-Based Prediction of Pharmacokinetics in the Renal Impairment Population.Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling
P2860
Q27020967-89DADB7B-2CF7-484C-8113-2750C4C92741Q34099766-EBB1B3DD-7FB3-4CC6-A260-FAB1B273B4C1Q35560052-245B088F-0859-40B3-B077-5FF89DEED7BDQ36025902-769739E1-6CC8-4715-8A98-37EB31627695Q36910606-60EBB47A-D9CC-484F-93B1-87A4AAE26E46Q37726177-98F81EA9-5067-4CCD-AB08-7D03A40F7EFAQ37978192-5768ECA0-F178-4556-83CD-6179B179A811Q37998136-4AD188C4-214F-48DB-9853-7795AD41263EQ38014312-947FD809-F973-4D8B-8561-4DB08B6381FFQ38087695-04019282-8BFF-4774-A841-68944F37AB29Q38287050-CEF31F4D-F4AC-4199-A9B2-602F4A77DAB3Q38462784-C5FE3573-9797-4432-A0E1-7AAB3E654D07Q38599220-EC6ACA78-C5D2-4866-8366-8EC8F62B4870Q38664509-C857E157-4BCE-47D9-AE06-58925D77E7BCQ38699135-CF9E8AD6-63EB-4EB9-991B-88D8D210BCA7Q38768114-54B80BDC-A246-494B-B9B6-DD7BC16B0124Q38817612-CC85D520-6C98-4E31-BE92-EA2029D43E88Q39133110-0995F0C9-513A-413B-8DD8-F39A0F86241FQ40072776-637C2AA1-5489-47D5-A524-716E1936A84AQ40431727-24E87404-8AAB-43E4-B985-CD5A9A34760FQ40882268-32CD3DB7-8D17-4AF3-9827-87F24ECD5882Q41617023-05CEDA6C-B50A-4B45-9C96-F022B8CF3CC4Q41768726-F8F66C95-1B0B-4F97-A6DD-66BC1EE39D4BQ41839399-0E2573AC-CC55-4542-9016-8F731481E653Q42280497-F11A382C-4C9B-4F42-AACE-D38DA13E73B0Q42608257-A547EE1F-8588-4A86-A5E8-325B7889CC14Q46379587-3DDE68E9-8367-441D-A127-F3E21BB21DE1Q46675919-83F1CC7D-94ED-4D17-9B49-559BE68F6695Q47813133-87EB2445-66D8-4D36-B82C-917C2A712184Q48114772-A255F0C5-B785-4862-BB84-71C0C0AFD773Q50120162-125DACFC-4B34-42A4-BF8A-70FAF98866EAQ53233045-F2705459-135F-4F70-A173-907D6AF02A12Q59152982-96E196F7-A529-42DA-9759-40AB512FE0CC
P2860
Modeling and predicting drug pharmacokinetics in patients with renal impairment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Modeling and predicting drug pharmacokinetics in patients with renal impairment.
@en
Modeling and predicting drug pharmacokinetics in patients with renal impairment.
@nl
type
label
Modeling and predicting drug pharmacokinetics in patients with renal impairment.
@en
Modeling and predicting drug pharmacokinetics in patients with renal impairment.
@nl
prefLabel
Modeling and predicting drug pharmacokinetics in patients with renal impairment.
@en
Modeling and predicting drug pharmacokinetics in patients with renal impairment.
@nl
P2093
P2860
P356
P1476
Modeling and predicting drug pharmacokinetics in patients with renal impairment
@en
P2093
Amin Rostami-Hodjegan
Karen Rowland Yeo
Masoud Jamei
P2860
P304
P356
10.1586/ECP.10.143
P407
P577
2011-03-01T00:00:00Z